HARTFORD, Conn. (AP) — Six generic drugmakers are asking a federal judge in Connecticut to dismiss a 40-state lawsuit accusing them of artificially inflating and manipulating prices to reduce competition for antibiotic and oral diabetes medication.
The companies filed documents Monday citing a variety of reasons including that the states failed to adequately allege deceptive conduct and that the states lack standing to sue on behalf of their citizens.
The companies include Heritage Pharmaceuticals, of Eatontown, New Jersey; Aurobindo Pharma USA, of East Windsor, New Jersey; Citron Pharma, of East Brunswick, New Jersey; Mayne Pharma USA, of Raleigh, North Carolina; Mylan Pharmaceuticals of Canonsburg, Pennsylvania; and Teva Pharmaceuticals USA of North Wales, Pennsylvania.
Connecticut Attorney General George Jepsen says an investigation into “suspicious” generic drug price increases found evidence “of collusion and anticompetitive conduct” among drugmakers.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Phoenix-area mayors ready to join forces to land Amazon headquarters
- Feds buy land to open up access to 2 Arizona forest areas
- Main Street Minute: Big-name companies set to attend Phoenix job fair
- Target is raising minimum hourly wage to $15 by end of 2020
- Tucson shooting memorial picks up $61K from National Park Service